AR062721A1 - Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla - Google Patents

Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla

Info

Publication number
AR062721A1
AR062721A1 ARP070103983A ARP070103983A AR062721A1 AR 062721 A1 AR062721 A1 AR 062721A1 AR P070103983 A ARP070103983 A AR P070103983A AR P070103983 A ARP070103983 A AR P070103983A AR 062721 A1 AR062721 A1 AR 062721A1
Authority
AR
Argentina
Prior art keywords
prepare
oral administration
compound
pharmaceutical composition
medicinal product
Prior art date
Application number
ARP070103983A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR062721A1 publication Critical patent/AR062721A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion farmacéutica de liberacion modificada para administracion oral que comprende una pluralidad de mini-comprimidos, teniendo dichos mini-comprimidos un diámetro menor de 5 mm y comprendiendo una cantidad terapéuticamente eficaz de un compuesto de pirrolidiniletenosulfonamida, inhibidor del Factor Xa dentro de una matriz de uno o más polímeros. El compuesto puede ser (E)-2-(5-clorotien-2-il)-N-{(3S)-1[(1S)-1-metil-2-morfolin-4-il-2-oxoetil]-2-oxopirrolidin-3-il}etenosulfonamida (ôCompuesto Aö) o (E)2-(5-cloro-2-tienil)-N-[(3S)-2-oxo-1-(2,3,4,5-tetrahidro-1H-2- benzazepin-7-il]-3-pirrolidinil]eteno sulfonamida. (ôCompuesto Bö). Los mini-comprimidos están contenidos en una cápsula o bolsita (sachet) con recubrimiento entérico. Su uso para preparar un medicamento y proceso para preparar dicha composicion.
ARP070103983A 2006-09-12 2007-09-10 Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla AR062721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82531406P 2006-09-12 2006-09-12

Publications (1)

Publication Number Publication Date
AR062721A1 true AR062721A1 (es) 2008-11-26

Family

ID=38835794

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103983A AR062721A1 (es) 2006-09-12 2007-09-10 Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla

Country Status (16)

Country Link
US (1) US20090285887A1 (es)
EP (1) EP2061439A1 (es)
JP (1) JP2010502762A (es)
KR (1) KR20090052346A (es)
CN (1) CN101516355A (es)
AR (1) AR062721A1 (es)
AU (1) AU2007296311A1 (es)
BR (1) BRPI0716234A2 (es)
CA (1) CA2662542A1 (es)
CL (1) CL2007002618A1 (es)
EA (1) EA200970267A1 (es)
IL (1) IL197295A0 (es)
MX (1) MX2009002669A (es)
PE (1) PE20080661A1 (es)
TW (1) TW200824723A (es)
WO (1) WO2008031782A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN101006076B (zh) 2004-06-24 2010-09-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミドの固体形態
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
ES2769357T3 (es) * 2009-06-16 2020-06-25 Pfizer Formas farmacéuticas de apixaban
WO2010151745A1 (en) * 2009-06-25 2010-12-29 Elite Laboratories, Inc. Oral dosage forms
AU2015271995A1 (en) * 2010-02-25 2016-01-21 Bristol-Myers Squibb Holdings Ireland Apixaban formulations
RS59593B1 (sr) * 2010-02-25 2020-01-31 Bristol Myers Squibb Holdings Ireland Formulacije apiksabana
AU2011293135A1 (en) * 2010-08-27 2013-04-11 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP3387992A1 (en) 2010-10-15 2018-10-17 Brain Sentinel, Inc. Method and apparatus for detecting seizures
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
WO2013174498A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
CN104582692A (zh) 2012-08-28 2015-04-29 中化帝斯曼制药有限公司荷兰公司 包含抗生素和β-内酰胺酶抑制剂的组合物，其中抗生素和β-内酰胺酶抑制剂中的至少一种是迷你片剂的形式
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US20190046449A1 (en) * 2016-02-25 2019-02-14 Mylan Inc. A unique high-shear granulation process for improved bioavailability of rivaroxaban
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301477T3 (es) * 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
AU3240900A (en) * 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Also Published As

Publication number Publication date
MX2009002669A (es) 2009-03-24
KR20090052346A (ko) 2009-05-25
BRPI0716234A2 (pt) 2013-10-15
EA200970267A1 (ru) 2009-08-28
US20090285887A1 (en) 2009-11-19
AU2007296311A1 (en) 2008-03-20
PE20080661A1 (es) 2008-06-12
IL197295A0 (en) 2009-12-24
TW200824723A (en) 2008-06-16
CN101516355A (zh) 2009-08-26
WO2008031782A1 (en) 2008-03-20
CA2662542A1 (en) 2008-03-20
JP2010502762A (ja) 2010-01-28
EP2061439A1 (en) 2009-05-27
CL2007002618A1 (es) 2008-03-14

Similar Documents

Publication Publication Date Title
AR062721A1 (es) Composicion farmaceutica de liberacion modificada para administracion oral que comprende una pluralidad de mini- comprimidos con un inhibidor del factor xa, su uso para prpeparar un medicamento y proceso para prepararla
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
CR10349A (es) Tabletas de paracetamol de liberacion rapida
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
BRPI0508342A (pt) formulações farmacêuticas
WO2011079239A3 (en) Combination tablet with chewable outer layer
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
UY28330A1 (es) Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
ECSP077242A (es) Formulación de comprimidos de liberación extendida que contiene pramipexol o una sal farmacéuticamente aceptable del mismo, un método para su fabricación y su uso
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
CL2007002967A1 (es) Forma cristalina a del compuesto 4-[3-(4-ciclopropancarbonil-piperazin-1-carbonil)-4-fluoro-bencil]-2h-ftalazin-1-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
CL2012001404A1 (es) Composicion farmaceutica que comprende microparticulas compresibles recubiertas de farmaco, un recubrimiento de liberacion modificada, enmascarador del sabor, que comprende un polimero insoluble en agua y un recubrimiento compresible con un edulcorante no polimero sobre ella; composicion de tabletas de rapida desintegracion oral; metodo de preparacion.
AR052225A1 (es) Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
PA8809601A1 (es) Combinación anti-retroviral
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
AR025938A1 (es) Nuevas composiciones farmaceuticas.
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure